論説
India's pharmaceutical industry has arrived at a cross roads. Well positioned compared with China as an arena for drug development and reliable, low cost manufacturing, India's pharma capabilities are strong and growing fast. Some large Indian players have already moved into global markets, and represent an emerging force as developers of generics.The scope of the opportunity is captured in a survey of 179 global pharmaceutical executives, conducted by Bain & Company and Knowledge@Wharton, with help from the Organisation of Pharmaceutical Producers of India (OPPI). With 45% of respondents from companies with headquarters in North America, the survey shows that global pharmaceutical executives believe India will figure prominently in their business five years from now.